AIT is a biotech company founded in 2011 by Mor Research Applications and based in Petah Tikva, Israel. The company develops formulations based on nitric oxide (NO) targeting infectious lung diseases such as bronchiolitis, cystic fibrosis, pneumonia, asthma and influenza. The University of British Columbia licensed the technology to AIT. AIT has completed $1.25M in funding and intends to use the capital to begin two clinical trials. Clalit Health Services, through its Soroka Medical Center, and Mor Research Applications will participate in the research and clinical trials. The company’s immediate plans focus on initiating those clinical studies using the newly raised capital.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2012